What’s the Deal with GLP-1 Microdosing?
Is Less Really More? When it comes to GLP-1 medications like Ozempic and Wegovy, that’s the question more providers and patients are starting to ask.
Originally approved for type 2 diabetes and later for obesity treatment, GLP-1 and other incretin-based therapies have rapidly gained traction in both clinical and consumer spaces. If you’re newer to prescribing or supporting GLP-1 therapy, I’ve put together a four-part series covering key considerations, including initiation, weight management, cost, and side effect mitigation.
Now, a new conversation is emerging: GLP-1 microdosing. What does microdosing mean in this context? Does it have clinical merit? And who might be a candidate?
Let’s explore the evidence, potential use cases, and the key questions we should be asking about the utility of microdosing.
First, What Is GLP-1?
GLP-1 stands for glucagon-like peptide-1, an incretin hormone naturally produced in the gut. It helps regulate blood glucose, slows digestion, and signals fullness to the brain.
Medications like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), which mimics both GLP-1 and GIP, are synthetic versions of these hormones. They are used to:
- Improve glycemic management in people with diabetes
- Support weight loss in individuals with overweight or obesity
- Reduce cardiovascular risk in certain patient populations
- Most recently, to treat moderate to severe obstructive sleep apnea
These medications are typically prescribed at FDA-approved doses and titrated gradually to manage gastrointestinal side effects like nausea, diarrhea, and upset stomach.
What Is Microdosing?
Microdosing typically refers to using a medication at a dose significantly lower than standard, often below the initial starting dose or maintained long term at the lowest therapeutic level. The practice dates back to the early 1990s, when it was used to safely study how newly developed drugs are absorbed, metabolized, and eliminated by the body.
In the context of GLP-1 medications, microdosing might look like:
- Remaining at 0.25 mg of semaglutide weekly, rather than titrating to higher maintenance doses
- Drawing a smaller dose from the pen using an insulin syringe or adjusting based on “clicks”
- Taking a low dose biweekly, monthly, or even on an “as-needed” basis, depending on the individual’s goals or tolerance
Why Are People Microdosing?
In short, there are several reasons why more people and providers are experimenting with microdosing, ranging from cost and access challenges to adverse side effects at standard doses, as well as off-label uses such as appetite suppression, management of acute and chronic inflammation, impulse control, and adjunctive support in type 1 diabetes.
Cost & Access
The out-of-pocket cost of GLP-1 medications can be exceptionally steep. Drugs like Ozempic or Wegovy often exceed $1,200 at the pharmacy, and even with insurance, co-pays and additional fees can add up quickly.
For a time, GLP-1 medications were in short supply, which contributed to the rise of compounding. In some cases, microdosing emerged out of necessity.
Now that the supply has stabilized, the FDA has removed GLP-1 therapies from the national shortage list, suggesting these medications should be easier to access. However, the high cost remains a significant barrier for many, often prompting individuals to stretch a single refill for as long as possible.
Adverse Side Effects
Microdosing can be particularly helpful for patients experiencing side effects. Allowing for small, incremental dose adjustments may improve tolerability and optimize long-term treatment outcomes.
In my experience working in endocrinology, we often supported patients using GLP-1 medications for type 2 diabetes by helping them “count the clicks” on their Ozempic pens. This approach enabled a gentler titration without requiring multiple pharmacy visits or burdensome prior authorizations.
Emerging evidence also suggests that microdosing may be a useful strategy during periods of acute illness or following hospital discharge, when lower doses may be better tolerated.
Reduced Appetite & Cravings
There has been a growing interest in using GLP-1 medications to help lose the “last 5 to 10 pounds,” often driven by aesthetic, metabolic, and preventive health goals.
A recent survey conducted by Tebra, a health research firm, found that out of 640 GLP-1 users, 36% reported microdosing the medication. Gen Z appeared to be leading the trend, with 89% of respondents aged 18 to 28 reporting they had microdosed in the past or were currently doing so.
Among all those who reported microdosing, almost 25% had been doing so for six months or longer. This suggests that some individuals may view microdosing as a more sustainable approach to achieving their weight loss goals.
Microdosing is also gaining traction for peri- and postmenopausal-related weight gain.
Acute & Chronic Inflammation
There has been growing interest in GLP-1 microdosing for managing both acute and chronic inflammation, particularly in conditions such as PCOS, cardiovascular disease, and even sports performance.
A recent Wall Street Journal article explores how recreational athletes, including runners, cyclists, and triathletes, are increasingly using GLP-1 medications to enhance performance by reducing body weight, improving endurance, and accelerating recovery.
Microdosing is being used to support improvements in VO₂ max, muscle mass, and metabolic markers. The goal is to avoid significant appetite suppression, which could lead to underfueling and negatively affect performance and recovery.
Interestingly, the World Anti-Doping Agency (WADA) has taken notice. In 2024, semaglutide was added to its anti-doping Monitoring Program.
Addiction & Impulse Control
Researchers are investigating GLP-1 therapy for its potential in addressing substance use disorders. Preclinical findings suggest that these medications may reduce drug use and cravings by changing reward pathways, stress responses, and cognitive function.
Although clinical research is still in its early stages, practice-based reports from individuals using microdosing for this purpose suggest potential benefits in managing alcohol, opioid, stimulant, and tobacco use disorders, while minimize the risks of weight loss, gastrointestinal side effects, and hypoglycemia.
Type 1 Diabetes
GLP-1 medications are not currently approved for use in type 1 diabetes, despite their potential benefits. It is well known that insulin is not the only hormonal deficiency in type 1 diabetes. The autoimmune process that destroys insulin-producing beta cells also impairs the broader islet cell population, leading to reductions in other hormones involved in metabolic regulation, including amylin, glucagon, and ghrelin.
Ginger Vieira, author, speaker, podcast host, and type 1 diabetes advocate, has shared her personal experience with microdosing semaglutide as part of her diabetes management plan.
In a recent YouTube video, she explains that a standard 1.0 mg dose of Ozempic was far too much for her petite, insulin-sensitive body. While she could tolerate the 0.25 mg initiation dose, even that level increased her risk of hypoglycemia.
Working closely with her diabetes care team, she found that a lower microdose of 0.15 mg, drawn from the pen using a U-100 insulin syringe, was effective. At this dose, she has been able to reduce her insulin needs, maintain weight stability, and feel more confident in her diabetes self-management plan.
Does Microdosing Work?
The truth is, because microdosing is largely experimental and not authorized by the FDA or drug manufacturers, there are no established guidelines. Reliable information on the safety, effectiveness, or long-term outcomes of this practice remains limited.
That said, some individuals and healthcare providers have reported positive results in specific cases, particularly when microdosing is used to improve tolerability or address off-label needs.
It should go without saying that this practice must be highly individualized and conducted under the supervision of a knowledgeable, credentialed healthcare provider. This is not a DIY endeavor. A lower dose does not necessarily mean lower risk.
Final Thoughts
Microdosing GLP-1s is gaining attention as patients and providers alike explore sustainable, lower-intensity approaches to support metabolic health.
But before endorsing off-label strategies like slicing pens or stretching prescriptions, it’s essential to individualize care. There’s no universal approach to GLP-1 therapy—and sometimes, less isn’t more. It’s just less.
- Collins L, Costello RA. Glucagon-like peptide-1 receptor agonists. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2025. http://www.ncbi.nlm.nih.gov/books/NBK551568/. Accessed July 5, 2025.
- Commissioner O of the. Fda approves first medication for obstructive sleep apnea. FDA. https://www.fda.gov/news-events/press-announcements/fda-approves-first-medication-obstructive-sleep-apnea. Published December 27, 2024. Accessed July 5, 2025.
- Resnick O, Bril F, Beauchamp G. Glucagon-like peptide-1 receptor agonists and type 1 diabetes: a potential game changer?. Front Endocrinol (Lausanne). 2025;15:1520313. Published 2025 Jan 21. doi:10.3389/fendo.2024.1520313
- MD ACJS Editor: Michael Natter. The six dysfunctional hormones of type 1 diabetes. T1D Exchange. September 2024. https://t1dexchange.org/t1d-hormones/. Accessed July 5, 2025.
- Lappin G, Noveck R, Burt T. Microdosing and drug development: past, present and future. Expert Opin Drug Metab Toxicol. 2013;9(7):817-834. doi:10.1517/17425255.2013.786042
- Komé AM, Chandran MM, Tungate Lopez SS, Buse JB, Klein KR. One size does not fit all: understanding microdosing semaglutide for diabetes in multidose pens. Diabetes Care. 2025;48(3):e25-e27. doi:10.2337/dc24-2575
- Microdosing GLP-1 medications: A new weight-loss trend? https://www.tebra.com/theintake/healthcare-reports/microdosing-glp-1. Accessed July 6, 2025.
- Bruns Vi N, Tressler EH, Vendruscolo LF, Leggio L, Farokhnia M. IUPHAR review – Glucagon-like peptide-1 (GLP-1) and substance use disorders: An emerging pharmacotherapeutic target. Pharmacological Research. 2024;207:107312. doi:10.1016/j.phrs.2024.107312
Discover more from Sarah Hormachea
Subscribe to get the latest posts sent to your email.
